Geoffroy Pineau-Valencienne practices in the area of corporate law with particular focus on venture capital, private equity, M&A, and capital markets. He represents a large number of listed and unlisted high-growth companies at every stage of development, as well as their managers and investors, particularly in the life sciences and technology industries.
In addition, he has significant experience drafting and negotiating commercial agreements and representing industrial groups and emerging companies in connection with R&D licensing and distribution agreements.
Geoffroy's recent experience includes representation of technology and life sciences companies such as Alizé Pharma, Amoéba, Cellectis, Cellnovo, Criteo, Diaxonhit, Genticel, HRA Pharma, Inotrem, Mauna Kea Technologies, Otonnale, Talend, and Trace One. These transactions include the initial public offerings of Amoéba, Genticel, and Enertime on the main or Alternext market of Euronext Paris and of American Depositary Shares (ADS) of Talend on the NASDAQ Global Market, as well as follow-on offerings of Cellectis and Talend on NASDAQ. He also has worked on French and international M&A transactions involving the reverse sale of Genticel to Genkyotex and sale by Alizé Pharma Group of two subsidiaries respectively to Jazz Pharmaceuticals and Millendo Therapeutics.
Geoffroy has represented investors such as Andera Partners, Balderton Capital, BioMed Partners, Bpifrance, CEA Investissement, CITA Investissement, Entrepreneur Venture Gestion, HI Inov, Idinvest Partners, Riverside, Serena Capital, Seventure Partners, Ventech, Wellington Partners, Western Digital, and Xerys Gestion. These representations include Wellington Partners and others in connection with their co-investment in UroMems and TriCares and Idinvest Partners in connection with its investment in Lendix.
- New York University (LL.M. in Business Law 2002); Université de Paris II-Panthéon Assas (DESS in Business Law and Taxation 1998; Maîtrise with high honors 1997)
- Paris Bar
Acknowledged as the #1 venture capital team in France since 2000 in several top legal rankings
1st prize for IPOs and capital markets, Le Magazine des Affaires (2015 and 2016)
Paris M&A team ranked Band 1 in "Mid-cap M&A" in France, Option Droit & Affaires (2015, 2016, and 2017)
- English, French